Liquid Biopsy at Baseline Adds Prognostic and Predictive Value in mCRC  – International Society of Liquid Biopsy

International Society of Liquid Biopsy shared a post on X:

“Liquid Biopsy at Baseline Adds Prognostic and Predictive Value in mCRC

From the FIRE-4 (AIO-KRK-0114) Study — Stintzing et al., Journal of Clinical Oncology 2025

Key Highlights:

•  13% of RASwt patients by tissue were RASmut on liquid biopsy (LB)
• RASmut and BRAFV600E mutations detected by LB were linked to significantly shorter PFS and OS
• Patients with RASmut had better outcomes with switch maintenance to bevacizumab vs continued cetuximab
• 15.3% of initially RASwt patients converted to RASmut at progression—more frequent with prolonged cetuximab
• LB detects heterogeneity and emerging resistance, reinforcing its clinical utility

This study confirms LB’s role in improving real-time decision-making in mCRC and suggests it may outperform tissue testing in mutation detection at baseline.”

“Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study”

Authors: Sebastian Stintzing et al.